Lyophilized mRNA-lipid nanoparticles vaccine with long-term stability and high antigenicity against SARS-CoV-2

Liangxia Ai; Yafei Li; Li Zhou; Hao Zhang; Wenrong Yao; Jinyu Han; Junmiao Wu; Ruiyue Wang; Weijie Wang; Pan Xu; Zhouwang Li; Chengliang Wei; Haobo Chen; Jianqun Liang; Ming Guo; Zhixiang Huang; Xin Wang; Zhen Zhang; Wenjie Xiang; Bin Lv; Peiqi Peng; Shangfeng Zhang; Xuhao Ji; Zhangyi Li; Huiyi Luo; Jianping Chen; Ke Lan; Yong Hu.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-479867

Documentos relacionados

  1. Induction of Broadly Cross-Reactive Antibody Responses to SARS-CoV-2 Variants by S1 Nanoparticle Vaccines.
  2. Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants.
  3. Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2.
  4. Circular RNA vaccines against SARS-CoV-2 and emerging variants.
  5. The Life of SARS-CoV-2 Inside Cells: Replication-Transcription Complex Assembly and Function.
  6. Helper-Polymer Based Five-Element Nanoparticles (FNPs) for Lung-Specific mRNA Delivery with Long-Term Stability after Lyophilization.
  7. Bivalent mRNA vaccines against three SARS-CoV-2 variants mediated by new ionizable lipid nanoparticles.
  8. Trivalent mRNA Vaccine against SARS-CoV-2 and Variants with Effective Immunization.
  9. Lyophilization of Nanoparticles, Does It Really Work? Overview of the Current Status and Challenges.
  10. Nano-carrier DMSN for effective multi-antigen vaccination against SARS-CoV-2.